JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120272

Riluzole (PK 26124), GABA uptake inhibitor

Be the first to review this product! Submit a review

|

(3 Publications)

MW 270.66 Da, Purity >99%. Neuroprotective agent with anticonvulsant, sedative, anxiolytic, anti-ischemic and anesthetic properties. Inhibits glutamate release, enhances glutamate uptake, blocks voltage-dependent Na+ channels, antagonises NMDA receptors and inhibits GABA uptake. Reported to offer neuroprotection and some therapeutic potential for amyotrophic lateral sclerosis and Huntingdon's disease.
1 Images
Chemical Structure - Riluzole (PK 26124), GABA uptake inhibitor (AB120272)
  • Chemical Structure

Lab

Chemical Structure - Riluzole (PK 26124), GABA uptake inhibitor (AB120272)

2D chemical structure image of ab120272, Riluzole (PK 26124), GABA uptake inhibitor

Key facts

CAS number

850608-87-6

Purity

>99%

Form

Solid

form

Molecular weight

270.66 Da

Molecular formula

C<sub>8</sub>H<sub>6</sub>ClF<sub>3</sub>N<sub>2</sub>OS

PubChem

6419992

Nature

Synthetic

Solubility

Soluble in DMSO to 100 mM

Soluble in water to 10 mM

Biochemical name

Riluzole hydrochloride

Biological description

Neuroprotective agent with anticonvulsant, sedative, anxiolytic, anti-ischemic and anesthetic properties. Inhibits glutamate release, enhances glutamate uptake, blocks voltage-dependent Na+ channels, antagonises NMDA receptors and inhibits GABA uptake. Reported to offer neuroprotection and some therapeutic potential for amyotrophic lateral sclerosis and Huntingdon's disease.

Canonical smiles

C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl

InChi

InChI=1S/C8H5F3N2OS.ClH/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5;/h1-3H,(H2,12,13);1H

InChiKey

QEAOELIJQRYJJS-UHFFFAOYSA-N

IUPAC Name

6-(trifluoromethoxy)-1,3-benzothiazol-2-amine;hydrochloride

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient
Storage information
The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Glutamate Transporter 1 (GLT-1) also recognized as Excitatory Amino Acid Transporter 2 (EAAT2) is essential for regulating the levels of glutamate in the central nervous system. This protein features a mass of approximately 70 kDa and is largely expressed in astrocytes within the brain. It operates by transporting glutamate from the extracellular space into the cells utilizing the sodium concentration gradient as a driving force. This active transport mechanism prevents the accumulation of glutamate in the synaptic cleft reducing excitotoxicity which is harmful to neural cells.
Biological function summary

GLT-1 serves to maintain neurotransmitter homeostasis critical for proper synaptic functioning. It is a part of the larger SLC1 (solute carrier family 1) protein family which includes other transporters with similar functions. GLT-1 works closely with other glutamate transporters to help ensure synaptic signalings such as sensory perception and cognition proceed without interruption or damage. By efficiently clearing excessive glutamate from synapses it helps protect neurons from excitotoxic stress which can lead to cell death.

Pathways

This transporter is integral in the glutamatergic signaling pathway which plays an important role in synaptic plasticity and memory formation. GLT-1 closely interacts with proteins involved in metabolic pathways such as the glutamate-glutamine cycle ensuring that glutamate is recycled efficiently without causing cellular stress. It is also linked with EAAT1 another member of the excitatory amino acid transporters working in tandem to modulate the balance of neurotransmitter levels.

Mutations or dysfunctions of GLT-1 have been implicated in neurological conditions such as amyotrophic lateral sclerosis (ALS) and epilepsy. In ALS the downregulation of GLT-1 can lead to insufficient clearance of glutamate contributing to motor neuron degeneration. This protein is additionally associated with EAAT2 which is often studied for its role in preventing excitotoxic damage that might exacerbate these neurologic conditions. Researchers are exploring therapeutics like riluzole to modulate GLT-1 activity and alleviate symptoms related to these diseases.

Product protocols

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

iScience 25:103922 PubMed35252816

2022

Conjunctive changes in multiple ion channels mediate activity-dependent intrinsic plasticity in hippocampal granule cells.

Applications

Unspecified application

Species

Unspecified reactive species

Poonam Mishra,Rishikesh Narayanan

Neuron 110:644-657.e6 PubMed34998469

2022

A novel reticular node in the brainstem synchronizes neonatal mouse crying with breathing.

Applications

Unspecified application

Species

Unspecified reactive species

Xin Paul Wei,Matthew Collie,Bowen Dempsey,Gilles Fortin,Kevin Yackle

European journal of pharmacology 718:493-501 PubMed23872399

2013

Riluzole attenuates the effects of chemoconvulsants acting on glutamatergic and GABAergic neurotransmission in the planarian Dugesia tigrina.

Applications

Unspecified application

Species

Unspecified reactive species

Latha Ramakrishnan,Zachary Dalhoff,Samantha L Fettig,Michael R Eggerichs,Briegette E Nelson,Bibita Shrestha,Amira H Elshikh,Pratima Karki
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com